Beijing Luzhu Biotechnology Co., Ltd, a leading developer of human vaccines and therapeutic biologics, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, with CICC as the sponsor. The Chinese firm previously secured a Series C financing round that valued the company at RMB 4.42 billion (USD 660 million).
Company Overview
Founded in 2001, Luzhu Bio has established itself as a pioneer in the biologics industry. The company offers a next – generation Fab – scFv double antibody development platform called Fabite, along with mammalian expression technology and biologics manufacturing capabilities. Luzhu Bio has developed multiple bacterial polysaccharide protein conjugate vaccines and high – purity hypo – pyrogenic polysaccharide vaccines. Notably, it became the world’s first company to develop a group A and C meningococcal polysaccharide conjugate vaccine.
Product Pipeline
Luzhu Bio’s product pipeline includes human vaccines, monoclonal antibodies (mAbs), and bispecific antibodies (BsAbs). Currently, the company has three clinical – stage product candidates: one vaccine candidate (LZ901) and two antibody injection candidates (K3 and K193). The core product LZ901, a recombinant shingles vaccine candidate developed in – house, is undergoing a Phase II clinical study and has been filed for a clinical trial in the US. Another key product, K3, is a biosimilar version of Humira (adalimumab) and has completed Phase I trials.-Fineline Info & Tech
